Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05162443
Title Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.